Corbus Pharmaceuticals(CRBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CRBP Corbus Pharmaceuticals

Closed 06-09 16:00:00 EDT

7.70

+0.14

+1.85%

盘后7.65

-0.05-0.65%

18:45 EDT

High7.94	Low7.45	Vol293.75K
Open7.56	D1 Closing7.56	Amplitude6.48%
Mkt Cap142.66M	Tradable Cap104.20M	Total Shares18.53M
T/O2.25M	T/O Rate2.17%	Tradable Shares13.53M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CRBP","market":"US","secType":"STK","nameCN":"Corbus Pharmaceuticals","latestPrice":7.7,"timestamp":1781035200000,"preClose":7.56,"halted":0,"volume":293748,"hourTrading":{"tag":"盘后","latestPrice":7.65,"preClose":7.7,"latestTime":"18:45 EDT","volume":1229,"amount":9463.5853,"timestamp":1781045154558,"change":-0.05,"changeRate":-0.006494,"amplitude":0.006494},"delay":0,"changeRate":0.018518518518518594,"floatShares":13532800,"shares":18527795,"eps":-5.660431,"marketStatus":"Closed","change":0.14,"latestTime":"06-09 16:00:00 EDT","open":7.56,"high":7.94,"low":7.4501,"amount":2251216.8749616,"amplitude":0.064802,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.660431,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1781078400000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":7.56,"preHourTrading":{"tag":"盘前","latestPrice":7.5138,"preClose":7.56,"latestTime":"09:18 EDT","volume":958,"amount":7229.544126,"timestamp":1781011124483,"change":-0.0462,"changeRate":-0.006111,"amplitude":0.029392},"postHourTrading":{"tag":"盘后","latestPrice":7.65,"preClose":7.7,"latestTime":"18:45 EDT","volume":1229,"amount":9463.5853,"timestamp":1781045154558,"change":-0.05,"changeRate":-0.006494,"amplitude":0.006494},"volumeRatio":0.533306,"impliedVol":1.1629,"impliedVolPercentile":0.6414},"requestUrl":"/m/hq/s/CRBP","defaultTab":"news","newsList":[{"id":"2642149074","title":"Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2642149074","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642149074?lang=en_us&edition=fundamental","pubTime":"2026-06-10 05:21","pubTimestamp":1781040060,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  rallied 1.85% to $7.70 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average  rising 0.17% to 50,872.11 and the NASDAQ Composite Index  falling 0.97% to 25,678.82.Corbus Pharmaceuticals Holdings Inc. closed 62.55% below its 52-week high of $20.56, which the company reached on October 20th.The stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as Vanda Pharmaceuticals Inc.  rose 3.03% to $6.12, Fortress Biotech Inc.  rose 2.81% to $2.93, and Viking Therapeutics Inc.  fell 0.03% to $29.23.Data source: Dow Jones Market Data, FactSet. Data compiled June 9, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641283631","title":"Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Friday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2641283631","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641283631?lang=en_us&edition=fundamental","pubTime":"2026-06-06 05:21","pubTimestamp":1780694460,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  shed 5.62% to $7.56 Friday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index  falling 4.18% to 25,709.43 and Dow Jones Industrial Average  falling 1.35% to 50,866.78.Corbus Pharmaceuticals Holdings Inc. closed 63.23% short of its 52-week high of $20.56, which the company reached on October 20th.The stock underperformed when compared to some of its competitors Friday, as Vanda Pharmaceuticals Inc.  fell 3.52% to $6.03, Fortress Biotech Inc.  fell 4.33% to $2.65, and Viking Therapeutics Inc.  fell 4.47% to $28.45.Trading volume  remained 132,328 below its 50-day average volume of 459,153.Data source: Dow Jones Market Data, FactSet. Data compiled June 5, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jo","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641167854","title":"Corbus Pharmaceuticals Holdings Inc. Stock Climbs 8.5%, Outperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2641167854","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641167854?lang=en_us&edition=fundamental","pubTime":"2026-06-05 04:32","pubTimestamp":1780605120,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc. rose 8.5% to $8.01 on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average rising 1.7% to 51,561.93 and the NASDAQ Composite Index falling 0.1% to 26,830.96.The stock's rise snapped a three-day losing streak.Corbus Pharmaceuticals Holdings Inc. closed 61.0% below its 52-week high of $20.56, which the company achieved on October 20th.The stock outperformed some of its peers, as Vanda Pharmaceuticals Inc. rose 2.6% to $6.25, Fortress Biotech Inc. rose 6.1% to $2.77, and Viking Therapeutics Inc. rose 1.53% to $29.78.Trading volume totaled 829,309, compared to the 50-day average of 444,970.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640135007","title":"Top Corbus Pharmaceuticals Executive Quietly Makes a Bold Insider Move","url":"https://stock-news.laohu8.com/highlight/detail?id=2640135007","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640135007?lang=en_us&edition=fundamental","pubTime":"2026-06-04 10:10","pubTimestamp":1780539001,"startTime":"0","endTime":"0","summary":"New insider activity at Corbus Pharmaceuticals ( ($CRBP) ) has taken place on June 3, 2026. Corbus Pharmaceuticals just saw a notable insider move ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-corbus-pharmaceuticals-executive-quietly-makes-a-bold-insider-move-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-corbus-pharmaceuticals-executive-quietly-makes-a-bold-insider-move-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640829281","title":"Corbus Chief Business Officer Nishant Saxena acquires $101,115 of common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2640829281","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640829281?lang=en_us&edition=fundamental","pubTime":"2026-06-04 05:37","pubTimestamp":1780522642,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals Chief Business Officer Nishant C. Saxena bought 13,500 common shares in open-market purchases.Saxena’s beneficial ownership rose to 75,300 shares following the transactions.Purchase prices were USD 7.33 per share on a weighted-average basis for part of the buying, rising to USD 7.58 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corbus Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL5v1TXV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Corbus Chief Business Officer Nishant Saxena acquires $101,115 of common shares","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640192628","title":"Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors Despite Losses On The Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2640192628","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640192628?lang=en_us&edition=fundamental","pubTime":"2026-06-03 05:21","pubTimestamp":1780435260,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  shed 2.71% to $7.54 Tuesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite Index  rising 0.03% to 27,093.90 and the Dow Jones Industrial Average  rising 0.45% to 51,307.79.This was the stock's second consecutive day of losses.Corbus Pharmaceuticals Holdings Inc. closed 63.33% below its 52-week high of $20.56, which the company reached on October 20th.The stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as Vanda Pharmaceuticals Inc.  fell 3.69% to $6.13, Fortress Biotech Inc.  rose 3.11% to $2.65, and Viking Therapeutics Inc.  fell 6.33% to $29.29.Trading volume  eclipsed its 50-day average volume of 423,548.Data source: Dow Jones Market Data, FactSet. Data compiled June 2, 2026.This content was created by MarketWatch, which is operated by Dow Jon","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640565910","title":"Corbus Pharmaceuticals (CRBP) Gets a Buy from Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2640565910","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640565910?lang=en_us&edition=fundamental","pubTime":"2026-06-02 19:38","pubTimestamp":1780400291,"startTime":"0","endTime":"0","summary":"In a report released today, Paul Jeng from Guggenheim maintained a Buy rating on Corbus Pharmaceuticals, with a price target of $45.00. According t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/corbus-pharmaceuticals-crbp-gets-a-buy-from-guggenheim-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/corbus-pharmaceuticals-crbp-gets-a-buy-from-guggenheim-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640675489","title":"Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Monday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2640675489","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640675489?lang=en_us&edition=fundamental","pubTime":"2026-06-02 05:20","pubTimestamp":1780348800,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  slid 2.02% to $7.75 Monday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite Index  rising 0.42% to 27,086.81 and the Dow Jones Industrial Average  rising 0.09% to 51,078.88.Corbus Pharmaceuticals Holdings Inc. closed 62.31% below its 52-week high of $20.56, which the company achieved on October 20th.The stock demonstrated a mixed performance when compared to some of its competitors Monday, as Vanda Pharmaceuticals Inc.  fell 1.32% to $6.37, Fortress Biotech Inc.  fell 8.21% to $2.57, and Viking Therapeutics Inc.  fell 4.49% to $31.27.Trading volume  eclipsed its 50-day average volume of 414,524.Data source: Dow Jones Market Data, FactSet. Data compiled June 1, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Do","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640966749","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Jasper Therapeutics (JSPR) and Corbus Pharmaceuticals (CRBP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640966749","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640966749?lang=en_us&edition=fundamental","pubTime":"2026-06-02 02:00","pubTimestamp":1780336841,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Jasper Therapeutics (JSPR) and Corbus Pharmaceutic...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-jasper-therapeutics-jspr-and-corbus-pharmaceuticals-crbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-jasper-therapeutics-jspr-and-corbus-pharmaceuticals-crbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","BK4585","CRBP","LU0128526141.USD","JSPR","BK4139","XBI","HCSG","BK4137","BK4588","LABU","BK4581","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639767055","title":"Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors On Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2639767055","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639767055?lang=en_us&edition=fundamental","pubTime":"2026-05-30 05:20","pubTimestamp":1780089600,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  advanced 3.53% to $7.91 Friday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index  rising 0.20% to 26,972.62 and the Dow Jones Industrial Average  rising 0.72% to 51,032.46.The stock's rise snapped a four-day losing streak.Corbus Pharmaceuticals Holdings Inc. closed 61.53% short of its 52-week high of $20.56, which the company reached on October 20th.The stock outperformed some of its competitors Friday, as Vanda Pharmaceuticals Inc.  fell 2.86% to $6.45, Fortress Biotech Inc.  fell 0.36% to $2.80, and Viking Therapeutics Inc.  rose 1.71% to $32.74.Trading volume  eclipsed its 50-day average volume of 397,251.Data source: Dow Jones Market Data, FactSet. Data compiled May 29, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is publishe","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638763186","title":"Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Wednesday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2638763186","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638763186?lang=en_us&edition=fundamental","pubTime":"2026-05-28 05:20","pubTimestamp":1779916800,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  slipped 1.14% to $7.82 Wednesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite Index  rising 0.07% to 26,674.73 and the Dow Jones Industrial Average  rising 0.36% to 50,644.28.This was the stock's third consecutive day of losses.Corbus Pharmaceuticals Holdings Inc. closed 61.96% below its 52-week high of $20.56, which the company achieved on October 20th.The stock underperformed when compared to some of its competitors Wednesday, as Vanda Pharmaceuticals Inc.  rose 3.86% to $6.46, Fortress Biotech Inc.  rose 2.60% to $2.76, and Viking Therapeutics Inc.  rose 2.79% to $31.66.Trading volume  eclipsed its 50-day average volume of 344,802.Data source: Dow Jones Market Data, FactSet. Data compiled May 27, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. Ma","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638516688","title":"Wedbush Sticks to Their Buy Rating for Corbus Pharmaceuticals (CRBP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638516688","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638516688?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:38","pubTimestamp":1779885523,"startTime":"0","endTime":"0","summary":"Wedbush analyst reiterated a Buy rating on Corbus Pharmaceuticals today and set a price target of $30.00. The word on The Street in general, sugges...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-sticks-to-their-buy-rating-for-corbus-pharmaceuticals-crbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-sticks-to-their-buy-rating-for-corbus-pharmaceuticals-crbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638040535","title":"Corbus Pharmaceuticals Holdings Inc : Wedbush Cuts Target Price to $30 From $38","url":"https://stock-news.laohu8.com/highlight/detail?id=2638040535","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638040535?lang=en_us&edition=fundamental","pubTime":"2026-05-27 19:16","pubTimestamp":1779880601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nFWN4240UU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638528557","title":"Corbus Pharmaceuticals Holdings Inc. Stock Slides 30.3%, Underperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2638528557","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638528557?lang=en_us&edition=fundamental","pubTime":"2026-05-27 04:33","pubTimestamp":1779827580,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc. plummeted 30.3% to $7.91 on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index rising 1.2% to 26,656.18 and the Dow Jones Industrial Average falling 0.2% to 50,461.68.This was the stock's second consecutive day of losses.Corbus Pharmaceuticals Holdings Inc. closed 61.5% short of its 52-week high of $20.56, which the company reached on October 20th.The stock underperformed when compared to some of its peers, as Vanda Pharmaceuticals Inc. rose 0.5% to $6.22, Fortress Biotech Inc. fell 1.8% to $2.69, and Viking Therapeutics Inc. fell 0.29% to $30.80.Trading volume totaled 3.7 million, compared to the 50-day average of 272,674.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638542183","title":"Corbus Pharmaceuticals Falls on Reports of Adverse Events in Tumor-Treatment Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2638542183","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638542183?lang=en_us&edition=fundamental","pubTime":"2026-05-27 02:59","pubTimestamp":1779821940,"startTime":"0","endTime":"0","summary":"Shares of Corbus Pharmaceuticals dropped after the biotechnology company reported data from its clinical study of a tumor treatment that showed adverse events among some patients.The stock slid 31%, to $7.81, midday Tuesday and is down about 4% year to date.The company, which focuses on treatments for cancer and obesity, on Tuesday reported data from its Phase 1/2 clinical study of CRB-701, an antibody-drug conjugate that targets a protein in certain solid tumors.The company said Grade 3 treatment-related adverse events were reported in 19.2% of patients and Grade 4 adverse events--which are life-threatening or disabling--were reported in 0.9% of patients.Corbus Pharmaceuticals said CRB-701 continued to be safe and well tolerated. The company is on track to start a registrational study of CRB-701 in the summer of 2026.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638549069","title":"Corbus Pharmaceuticals share selloff overdone, says Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2638549069","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638549069?lang=en_us&edition=fundamental","pubTime":"2026-05-27 00:58","pubTimestamp":1779814694,"startTime":"0","endTime":"0","summary":"Guggenheim views the weakness today in shares of Corbus Pharmaceuticals (CRBP) as overdone. The company’s CRB-701 data supports the drug’s “strong ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/corbus-pharmaceuticals-share-selloff-overdone-says-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/corbus-pharmaceuticals-share-selloff-overdone-says-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638954977","title":"Analysts Are Bullish on These Healthcare Stocks: LifeMD (LFMD), Corbus Pharmaceuticals (CRBP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638954977","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638954977?lang=en_us&edition=fundamental","pubTime":"2026-05-27 00:50","pubTimestamp":1779814207,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on LifeMD (LFMD), Corbus Pharmaceuticals (CRBP) and Car...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-lifemd-lfmd-corbus-pharmaceuticals-crbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-lifemd-lfmd-corbus-pharmaceuticals-crbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRBP","LFMD","BK4139","BK4183","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638549913","title":"Corbus Pharmaceuticals Price Target Maintained With a $40.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2638549913","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638549913?lang=en_us&edition=fundamental","pubTime":"2026-05-27 00:37","pubTimestamp":1779813420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRBP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 26, 2026 12:37 ET (16:37 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638516423","title":"Corbus reports 42.9% response rate for CRB-701 in Phase 1/2 second-line oropharyngeal cancer study","url":"https://stock-news.laohu8.com/highlight/detail?id=2638516423","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638516423?lang=en_us&edition=fundamental","pubTime":"2026-05-26 19:04","pubTimestamp":1779793489,"startTime":"0","endTime":"0","summary":"Corbus reported updated Phase 1/2 data for Nectin-4 ADC CRB-701 in second-line oropharyngeal cancer, cervical cancer.Results will be presented at the 2026 ASCO meeting.Study showed meaningful tumor shrinkage in both cancers, supporting a path toward late-stage development in HPV-driven disease.Safety profile remained broadly manageable, with low treatment discontinuations despite frequent eye-related side effects.Registrational TEMPO-1 trial in second-line oropharyngeal cancer remains on track to start in summer 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corbus Pharmaceuticals Holdings Inc. published the original content used to generate this news brief on May 26, 2026, and is solely responsible for the information contained ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDL32RLk6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638516159","title":"Corbus Pharmaceuticals Reports Updated Crb-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2638516159","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638516159?lang=en_us&edition=fundamental","pubTime":"2026-05-26 19:02","pubTimestamp":1779793337,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nFWN4230K5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.corbuspharma.com","stockEarnings":[{"period":"1week","weight":-0.0245},{"period":"1month","weight":-0.3102},{"period":"3month","weight":-0.247},{"period":"6month","weight":-0.2632},{"period":"1year","weight":-0.1809},{"period":"ytd","weight":-0.0713}],"compareEarnings":[{"period":"1week","weight":-0.0255},{"period":"1month","weight":0.0022},{"period":"3month","weight":0.0916},{"period":"6month","weight":0.0751},{"period":"1year","weight":0.2338},{"period":"ytd","weight":0.084}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.363358},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.048678},{"month":3,"riseRate":0.636364,"avgChangeRate":0.197993},{"month":4,"riseRate":0.545455,"avgChangeRate":0.046477},{"month":5,"riseRate":0.583333,"avgChangeRate":0.055971},{"month":6,"riseRate":0.25,"avgChangeRate":-0.063588},{"month":7,"riseRate":0.272727,"avgChangeRate":-0.050382},{"month":8,"riseRate":0.636364,"avgChangeRate":0.095672},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.086452},{"month":10,"riseRate":0.181818,"avgChangeRate":-0.124298},{"month":11,"riseRate":0.727273,"avgChangeRate":0.130055},{"month":12,"riseRate":0.272727,"avgChangeRate":-0.132264}],"exchange":"NASDAQ","name":"Corbus Pharmaceuticals","nameEN":"Corbus Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Corbus Pharmaceuticals(CRBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Corbus Pharmaceuticals(CRBP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Corbus Pharmaceuticals,CRBP,Corbus Pharmaceuticals股票,Corbus Pharmaceuticals股票老虎,Corbus Pharmaceuticals股票老虎国际,Corbus Pharmaceuticals行情,Corbus Pharmaceuticals股票行情,Corbus Pharmaceuticals股价,Corbus Pharmaceuticals股市,Corbus Pharmaceuticals股票价格,Corbus Pharmaceuticals股票交易,Corbus Pharmaceuticals股票购买,Corbus Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Corbus Pharmaceuticals(CRBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Corbus Pharmaceuticals(CRBP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}